IN8bio Announces Data Emerging From its Recently Unveiled Gamma-Delta T cell “Off-the-Shelf” Induced Pluripotent Stem Cell Platform

IN8bio, Inc. recently announced data emerging from the company’s recently unveiled iPSC-based gamma-delta T cell platform. iPSCs represent a significant step toward next generation approaches of cellular manufacturing for true allogeneic ‘off-the-shelf’ innate cell therapies, and further broaden the company’s capabilities around the expansion and genetic engineering of gamma-delta T cells.

“Our iPSC program is innovative and could provide a potentially unlimited ‘off-the-shelf’ source of gamma-delta T cells,” said Lawrence Lamb PhD, CSO, and co-founder of IN8bio. “This provides another tool to advance IN8bio’s gamma-delta T cell-based approaches to target cancer. Our team has achieved a number of firsts and are advancing iPSCs as an approach to Vd1+ based gamma-delta T cell therapies in addition to our ongoing work with Vd2+ cells. Our team continues to lead in the development of gamma-delta T cell therapies as we work towards transforming hope into reality for cancer patients.”

IN8bio presented data from the iPSC platform during both podium and poster presentations at the ASGCT 25^th Annual Meeting in Washington, DC, on May 16, 2022. These data demonstrated that donor cells could be programmed into iPSCs, expanded, then differentiated in a stepwise feeder-free process into gamma-delta T cells. The platform encompasses the ability to perform directed differentiation to both Vd1+ and Vd2+ cell sub-types. The iPSC derived gamma-delta T cells were characterized both morphologically, through cell surface markers, as well as functionally, through killing assays. The differentiated cells were shown to have normal karyotypes and robust cytotoxicity, which may exceed that of patient or donor derived cells. The company also demonstrated genetic engineering of the iPSC gamma-delta T cells through the transduction of a novel CAR construct targeting chlorotoxin and incorporating IN8bio’s drug resistant immunotherapy (DRI) technology.

The company will be hosting a Research & Development Workshop on May 17, 2022 from 6:00-8:00 p.m. EDT to provide company updates on its strategy and pipeline. The discussion will cover preclinical data from the iPSC platform, a review of clinical programs along with details on the Phase 1b/2 trial design in relation to the company’s anticipated investigational new drug application (IND) filing. Guest speakers will include Dieter Kabelitz, MD, from the University of Kiel in Germany, a world recognized expert on gamma-delta T cells, and Bruce Levine, PhD, from the University of Pennsylvania and the current President of the International Society for Cell & Gene Therapy (ISCT), who are both member of the company’s scientific advisory board. The webcast can be accessed on the Events & Presentations page of the company’s website. The ASGCT poster is available on the Events & Presentations page of the IN8bio website: https://investors.in8bio.com/news-events/events-presentations.

IN8bio is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cell product candidates for solid and liquid tumors. Gamma-delta T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. IN8bio’s DeltEx platform employs allogeneic, autologous, iPSC and genetically modified approaches to develop cell therapies, designed to effectively identify and eradicate tumor cells.

IN8bio is currently conducting two investigator-initiated Phase 1 clinical trials for its lead gamma-delta T-cell product candidates: INB-200 for the treatment of newly diagnosed glioblastoma and INB-100 for the treatment of patients with leukemia undergoing hematopoietic stem cell transplantation. IN8bio also has a broad portfolio of preclinical programs focused on addressing other solid tumor types. For more information, visit www.IN8bio.com.